AstraZeneca to Present New Cardiovascular Data on FARXIGA in Type 2 Diabetes At ACC 2019


WILMINGTON, Del.–(BUSINESS WIRE)–Data evaluating the cardiovascular (CV) effects of FARXIGA® (dapagliflozin), including hospitalization for heart failure (hHF) in adults with type 2 diabetes (T2D) have been selected for late-breaking clinical trial and oral presentations at the American College of Cardiology’s (ACC) 68th Annual Scientific Session on March 16-18. The data are the first sub-analyses from the Phase III DECLARE-TIMI 58 trial for FARXIGA. AstraZeneca will also present the latest r